Chrystal Louis, MD, MPH recently joined CRISPR Therapeutics as Vice President, Head of Medical Affairs. In this role, she is responsible for building and leading our new Medical Affairs organization across all therapeutic areas. Prior to CRISPR, she was an Executive Director in US Medical Affairs and the Medical Disease Lead for the Myeloid Franchise at Celgene/BMS. In this role, she was responsible for strategic development and tactical execution of the US Medical Plans specific to IDHIFA and SPRYCEL, as well as the US Launch Plans for INREBIC, REBLOZYL (in 2 indications) and CC-486. While at Celgene, she was also an Executive Director of Oncology in charge of the ABRAXANE franchise within the US Medical Affairs organization. Prior to her work at Celgene/BMS, she was a Medical Director in the Discovery group at Merrimack Pharmaceuticals. She is a board-certified Pediatric Oncologist who completed her fellowship training and was an attending physician at Texas Children’s Hospital and Baylor College of Medicine (BCM) before moving into the pharmaceutical industry. While at BCM, she also worked in the Center for Cell and Gene Therapy, under the direction of Drs Helen Heslop and Malcolm Brenner, as the principal investigator for a number of first-in-man and first-in-pediatrics studies using virus-specific T cell as well as CAR-T cell immunotherapeutics. Dr Louis has a BS in Chemistry and BA in Political Science from Southwestern University in Georgetown, TX. She obtained her Medical and Master of Public Health degrees from Tulane University in New Orleans, LA, and completed her Pediatric Residency training at the University of California at Davis.